Hepatocellular carcinoma
Conditions
Interventions
Case series:CalliSpheres drug-eluting bead loaded with raltitrexed
Sponsors
The First Affiliated Hospital of Zhengzhou University
Eligibility
Sex/Gender
All
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: 1. Aged >=18 years old male and female; 2. Patients who was confirmed as hepatocellular carcinoma by Histopathological or clinical diagnosis; 3. Unsuitable/not accepted surgical resection/percutaneous ablation or ablation failure; 4. Child-Pugh grade A or grade B; 5. BCLC stage is B; 6. The tumor nodules in the liver area are =3 months; 9. Understood and signed the informed consent form.
Exclusion criteria
Exclusion criteria: 1. have other primary tumors; 2. pregnant or lactating women; 3. Child-Pugh C grade; 4. BCLC stage was C and D; 5. severe hepatic jaundice; 6. Subjects with active internal bleeding, clear signs of bleeding or severe coagulopathy, severe infection or hemophilia; 7. heart, lung, kidney and other important organ failure; 8. allergic to raltitrexed and contrast agents; 9. Severe arteriovenous fistula can not be blocked; 10. Patients who cannot express exactly his/her feelings or had poor compliance.
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Overall Survival;Adverse Event; | — |
Primary
| Measure | Time frame |
|---|---|
| Progression free survival; | — |
Countries
China
Contacts
Public ContactHaixue Dai
Suzhou Hengrui Jiasheng Biomedical Technology Co., Ltd.
Outcome results
None listed